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============

Non-suicidal self-injury (NSSI) has been proposed as a new diagnostic entity in the section 3 (conditions for further study) of the fifth edition of the Diagnostic and Statistical Manual (DSM 5) \[[@CR1]\]. The introduction of this new category has been discussed extensively \[[@CR2]--[@CR4]\], with strong arguments both for the implementation (such as i.e. avoiding to falsely label adolescent self-injurers as having borderline personality disorder, and addressing a topic with a high prevalence rate) and for the opposite (i.e. incorrectly calling a behavior "non-suicidal" which is a clear risk factor for suicide attempts). There is still an ongoing debate about how to correctly define self-harming behaviors, with part of the scientific community using the term Deliberate Self Harm (DSH) to describe any self-directed harmful behaviors (indirect or direct), regardless of their suicidal intent \[[@CR5],[@CR6]\]. In contrast, NSSI defines only directly harmful behaviors without suicidal intent \[[@CR1]\].

It remains undisputed that NSSI is a very prevalent phenomenon among adolescents, with lifetime prevalence rates of at least one self-injuring event around 18% in community samples worldwide \[[@CR7],[@CR8]\]. First studies using the proposed section 3 DSM 5 criteria reported rates between 4% and 7% for adolescent community samples and around 50% for child and adolescent psychiatric samples (for review: see \[[@CR9]\]). A recent review also found prevalence rates of NSSI and DSH in adolescents to be comparable \[[@CR7]\]. A recent comparison of 12 European countries (using the definition of "direct self-injurious behavior", which seems close to both a NSSI and a DSH definition), reported a mean prevalence rate of 27.6% in adolescents reaching from 17.1% in Hungary to 38.7% in France \[[@CR10]\]. There are only very few studies assessing rates of NSSI in adult community samples. Klonsky reported a 5.9% lifetime prevalence rate of NSSI using a random digit dialing sample from the US \[[@CR11]\]. This inconsistency of high lifetime prevalence rates in adolescence and rather low lifetime prevalence rates in adults \[[@CR8]\] requires further exploration. One explanation might be a re-attribution in adulthood, considering adolescent NSSI as being "nothing important to report", which would lead to underestimation in studies about lifetime NSSI rates in adults. Furthermore, there might be a memory bias of adults not remembering how frequently they had engaged in NSSI in adolescence. Alternatively, it might be possible that NSSI has increased in recent years, however, no indication for a rise of prevalence rates was found in the two systematic reviews of the literature \[[@CR7],[@CR8]\]. Given that both NSSI and DSH are highly prevalent in community sample and emerge in adolescence, research about predictors of these behaviors are highly relevant as they could inform preventive interventions. As predictors can be best identified through longitudinal research, studies focusing on a longitudinal assessment have the potential to inform researchers and policy makers.

Given this questions, it seems worthwhile to pay a closer look to the longitudinal development of NSSI and DSH. We therefore performed a systematic literature review to include every study that assessed NSSI and DSH longitudinally. Aims of this review were to (1) assess the stability of prevalence rates of NSSI and DSH over time. Further, (2) to compare 12-month incidence rates of NSSI and DSH in adolescents and adults and (3) to identify predictors for NSSI and DSH that have been reported constantly in longitudinal research.

Review {#Sec2}
======

We performed a systematic review of the literature using Medline and OVID. As a search strategy we used the terms "NSSI", "DSH", "self-harm", "self-injury", "deliberate self-harm", "nonsuicidal self-injury" in conjunction with "longitudinal" or "course". Only studies written in English or German providing longitudinal data about NSSI or DSH and published before the 1^st^ of August 2014 were included. Only studies measuring NSSI/DSH at - at least - two consecutive points in the same individuals were included. We excluded studies focusing on self-harm in populations with pervasive developmental disorders or mental retardation or studies providing longitudinal data about predictors of NSSI or DSH but just measuring NSSI/DSH at one point in time (see Figure [1](#Fig1){ref-type="fig"}). This led to the inclusion of 43 studies (see Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}).Figure 1**Flow-chart of study selection.**Table 1**Longitudinal studies of NSSI from community and clinical samples (n = 22)AuthorsCountrypopulationAge at baselineNFollow-up periodOutcome**Community samplesYou et al., 2012 \[[@CR16]\]ChinaCommunity sampleMean age: 14.63 (SD: 1.25)24356 monthsBaseline: 24.9% (12 month prevalence)T1: 13.9% (6 month prevalence)10.7% of sample: NSSI at both time pointsFranklin et al., 2014 \[[@CR17]\]USACommunity sampleMean age: 24.37 (SD: 8.28)496 monthsBaseline: 100%, (cutting: sum: 248, mean: 5.06, SD: 7.44) Follow-up: 20 reported no cutting during the follow-up (but at baseline); cutting: sum:164, mean: 3.42 (SD: 6.08)Wan et al., 2014 \[[@CR18]\]ChinaCommunity sampleMean age: 16.1 (SD: 2.8), age range: 12--24 years139239 monthsBaseline NSSI: 17.0% (12 month prevalence)3 months follow-up: 10.5% (3 month prevalence)6 months follow-up: 7.8% (3 month prevalence)9 months follow-up: 8.8% (3 month prevalence)Hasking et al., 2013 \[[@CR26]\]; Tatnell et al., 2014 \[[@CR36]\]AustraliaCommunity sampleMean age: 13.89 (SD: 0.97), age range: 12--18 years197311.7 monthsBaseline: 8.3% (lifetime prevalence)T1: 11.9%3.8% initiated NSSIModén et al., 2013 \[[@CR15]\]SwedenRegister study of all adults in ScaniaAdults93644912 monthsIncidence rate: 91/100 000 (male), 128/100 000 (female)19.3% of males with recent NSSI have injured themselves in the three years before, as well as 23.9% of femalesHamza & Willoughby, 2014 \[[@CR19]\]CanadaUniversity sampleMean age: 19.15666: 466 with past or recent NSSI + 200 controls without NSSI from a larger sample of 115312 monthBaseline: 38% (lifetime prevalence)T1: 2% (incident NSSI)Beginners: New NSSI at T1: 5.72% of participants with NSSIRecovered: lifetime NSSI but no NSSI since one year before baseline: 41,31%Relapsers: lifetime NSSI, no NSSI one year prior to baseline but NSSI prior to T1: 9.96%Desisters: NSSI in 12 month prior to baseline but not in 12 month prior to T1: 28.39%Persisters: NSSI 12 months prior to baseline and T1: 14.62%You et al., 2014 \[[@CR20]\]ChinaCommunity sampleMean age: 14.63 (SD: 1.25)360012 monthsBaseline: 10.3% (6 month prevalence)T1: (6 months follow-up): 12.7%T2 (12 months follow-up): 9.2%Martin et al., 2014 \[[@CR37]\]AustraliaCommunity sampleMean age: 14.87 (SD: 0.95)189612 monthsBaseline: 6%T1: 12 months after baseline: 3.7% (incident NSSI)Prinstein et al., 2010 (Study 1) \[[@CR12]\]USACommunity sample adolescents8th grade37712 monthsBaseline: 7.4% (12 month prevalence)After one year: 3.2%Glenn & Klonsky, 2011 \[[@CR21]\]USACollege sample screened for NSSIMean age: 18.96 (SD: 1.57)Baseline: 81 12 month follow-up: 5112 monthsBaseline: 100% (lifetime prevalence)52% (6-month prevalence)12 month follow up: 62.7% NSSI (12 month prevalence)Whitlock et al., 2012 \[[@CR38]\]USACollege sampleMean age: 20.3 (SD: 4)146624 monthsBaseline: 13.7% (lifetime prevalence)New NSSI at year 1: 5.2%New NSSI year 2: 0.8%Cumulative prevalence: 19.7%Marshall et al., 2013 \[[@CR27]\]SwedenCommunity sampleMean age: 13.21 (SD: 0.57)50624 monthsBaseline: 0.20 (6 months: mean of Deliberate Self Harm Inventory item scores)T1: 0.24T2: 0.25Barrocas et al., 2014 \[[@CR22]\]ChinaCommunity sampleMean age: 16.02 (SD: 0.61)61724 months (assessment every 3 months)T1 (3 months after baseline): 23.8%T2: 17.6%T3: 17.2%T4: 11.4%T5: 13.8%T6: 12.2%T7: 11.5%T8: 11.1% (all 3 months prevalence)Voon et al., 2014 \[[@CR28]\]AustraliaCommunity sampleMean age: 13.9 (SD:. 0.99)314324 monthsBaseline: 8.1%T1: 24 months after baseline: 10,1% (lifetime prevalence)Hankin & Abela, 2011 \[[@CR29]\]USACommunity sample*M* age = 12.63, *SD* = 1.2597 at both waves30 monthsBaseline: 8% (12 month prevalence)Follow up: 18% newly initiated: 14%Continuation: 50% (n = 4)Baetens et al., 2014 \[[@CR30]\]BelgiumCommunity sampleMean age: 12 years533 (all time points)30 monthsBaseline: 5.15% lifetime prevalenceT1: 12 months after baseline: 2.78% (12 month prevalence)T2: 30 months after baseline: 5.31% (12 month prevalence)Cumulative: 10.70% (lifetime prevalence)Clinical samples or clinical studiesRosenbaum Asarnow et al., 2011 \[[@CR39]\]USAParticipants of depression treatment study xMean age: 14.2 (SD: 1.2)3276 monthsBaseline: 23.9% NSSI alone, 14% NSSI and suicidal attemptT1: 11% incidence rateWilkinson et al., 2011 \[[@CR40]\]UKParticipants of depression treatment studyMean age: 14.2 (SD: 1.2)1637 monthsBaseline: 36% (1 month prevalence)T1: 37% (during follow-up)Guerry & Prinstein, 2010 \[[@CR23]\]USAChild and adolescent psychiatric inpatientsMean age: 13.51 (SD: 0,75), age range: 12--15 years14318 monthsBaseline: 67,9% (12 month prevalence)T1: 3 month: 32.7% (last 3 month)T2: 6 month: 29.0%T3: 9 months: 34.0%T4: 15 months: 22.8%T5: 18 months: 28.4%Prinstein et al., 2010 (Study 2) \[[@CR12]\]USAChild and adolescent psychiatric inpatientsMean age: 13.51 (SD: 0,75), age range: 12--15 years14018 monthsBaseline 1.14T1: 9 months: 1.11, T2: 18 months: 1.10 (mean score of NSSI behaviors: 12 month prevalence)McGlashan et al., 2005 \[[@CR24]\]USAPatients with personality disordersAdults, age range: 18-45474 (201 with Borderline Personality disorder)24 monthsBaseline: 60%T1: 24 months: 30%, remission in 46%Tuisku et al., 2014 \[[@CR25]\]FinlandAdolescent outpatientsMean age: 16.513996 monthsBaseline: 32.4%T1: 12 months after baseline: 21.7% (12 months prevalence)T2: (96 months after baseline): 16.1%T1: first assessment after baseline.T2-Tx: consecutive assessments.N is provided for the last wave of the respective studies to describe participants being included in the longitudinal design.Studies are sorted by follow-up time-frame.Table 2**Longitudinal studies of DSH from community and clinical samples (n = 9)StudyCountryPopulationAge at baselineNFollow-up periodOutcomes**Community samplesO´Connor et al., 2009 \[[@CR31]\]ScotlandCommunity sampleMean age: 15.2 (SD: 0.72), age range: 15--16 years5006 monthsbaseline: 9.5% (12 month prevalence)T1: 6.2% (6 month prevalence)2.6% for the first time3.6% repeatersLundh et al., 2011 \[[@CR41]\]SwedenCommunity sampleGrade 7 and 8879 at both waves12 monthsbaseline: 45.1% (female) and 37.9% (male) (6 month prevalence)Bjärehed et al., 2012 \[[@CR42]\]incidence rate: 10.4% (female), 8% (male)Larsson & Sund, 2008 \[[@CR33]\]USACommunity sample adolescentsMean age: 13.7 (SD: 0.58), age range: 12--15 years236012 monthsbaseline: 4.2%T1: 12.7% (12 months)incidence rate: 2.4%Stallard et al., 2013 \[[@CR43]\]UKCommunity sample12-16 years395512 monthsbaseline: 9.6% (6 month prevalence)T1: 10.9% (6 month prevalence)cumulative: 15% DSH during study period55.1% continued DSH after one yearWichstrom, 2009 \[[@CR44]\]NorwayCommunity sample adolescentsMean age: 16.5 years (SD: 1.9)292460 monthsbaseline: 2.4% (lifetime prevalence)T1: 2.2% (during follow-up period)9.9% of baseline DSH continuedRossow & Norström, 2014 \[[@CR32]\]NorwayCommunity sampleMean age: 16.5, age range: 14-21264760 monthsbaseline: 3.2% (12 month prevalence)T1: 1.6%stable DSH at both points: 0.30%, decrease in DSH: 2.9%new DSH. 1.3%Moran et al., 2012 \[[@CR13]\]AustraliaCommunity sampleMean age: 15.9 (SD 0.49)1652 (responding to questions of DSH at least once in adolescence and once in adulthood)174 monthsfirst assessment of DSH at wave three (baseline of DSH): 5.1% (12 month prevalence)at wave 9: 0.5% (6 month prevalence)any self harm during adolescence: 8.3%, any self-harm during young adulthood: 2.6%only cutting/burning: 4.6% in adolescent phase1.2% in young adult phasenew DSH in young adulthood: 1.6% remission in young adulthood: 7.4%, continuation in young adulthood: 0.8%Clinical samples/samples from hospitalsHawton et al., 2012 \[[@CR45]\]UKIndividuals presenting with self harm to hospital0-18 years520572 monthsRepetition of DSH: 27.3%17.1% of self harm epidsodes: self-injurySinclair et al., 2010 \[[@CR46]\]UKClinical sample: self harm patients: 94% self-poisoning, 4% self-injury, 2% both self-poisoning and self-injuryMedian age: 28.4 years14374 monthsFurther self-harm in 57.4%Wedig et al., 2012 \[[@CR14]\]USAClinical sample: Patients with Borderline personality disorderMean age: 26.9 years231192 months (16 years, Tx every 2 years)Baseline: 90.3%T1: 50.9%T2: 35.3%T3: 28.4%T4: 22.4%T5: 17.7%T6: 23.0%T7: 18.5%T8: 14.3%T1: first assessment after baseline.N is provided for the last wave of the respective studies to describe participants being included in the longitudinal design.

Results {#Sec3}
=======

Of the 32 studies selected, 22 (69%) represented studies on NSSI, whereas ten studies (31%) used a definition of DSH (see Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). Combining both, 24 (75%) of the studies presented data from community samples and nine studies (25%) reported data from clinical samples or from clinical studies (including the study by Prinstein et al. \[[@CR12]\], presenting data both from a community and a clinical sample; for details see Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). Twenty-five (78%) of all studies reported on participants who were in their adolescence during baseline.

On average, duration of follow-up was 19.53 months (SD: 18.76) in studies concerning NSSI and 67.4 months (SD: 66.7) in studies concerning DSH. Although the huge difference was driven by the studies by Moran et al., \[[@CR13]\], and Wedig et al., \[[@CR14]\] who provided a follow-up for around 15 and 16 years respectively concerning DSH, exclusion of these outliers still yielded a result of a longer follow-up period in DSH studies (M = 38.5 months, SD = 30.4). Number of participants encompassed N = 969,197 in studies on NSSI (mean number of participants: N = 44,054; SD = 199,341). As this number was mainly due to the large number of participants from a registry study \[[@CR15]\], calculations after exclusion of this study showed smaller numbers (N = 32,748; mean number of participants: N = 1,559; SD = 3,025). Overall, 20,496 individuals participated in longitudinal studies of DSH (mean number: N = 2,049, SD = 1,688).

Developmental course of NSSI and DSH {#Sec4}
------------------------------------

It was possible to retrieve data about decline or increase of rates from 17 studies on NSSI and five studies on DSH. There was a decrease in rates of NSSI during the follow-up in 12 (\[[@CR12]\]: both study populations; \[[@CR16]--[@CR25]\]) and an increase in five (\[[@CR26]--[@CR30]\]) of these 17 studies on NSSI. The course of NSSI throughout adolescence is shown in Figure [2](#Fig2){ref-type="fig"}. However, only seven studies provided data on community samples of adolescents measuring the same time-frame of prevalence (i.e. 6-months prevalence) of NSSI at all time-points.Figure 2**Studies on prevalence of NSSI in adolescent community samples.** Only studies giving information about mean age of participants, and which used the same prevalence measures for each time-point, were included. For individual prevalence time-frames (i.e. 3-months, 6 months, etc.) of each study see Table [1](#Tab1){ref-type="table"}.

Interestingly, five out of the six studies showing an increase of rates of NSSI, were performed in younger adolescents. A decrease in NSSI was mainly found in older adolescents and adults (see Figure [2](#Fig2){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}).

An incidence rate of NSSI within a 12 month time frame was provided in five studies of NSSI in community samples of adolescents and young adults (mean incidence rate: 4.32%, SD: 1.08). In studies using a DSH definition, a decline was described in four (\[[@CR13],[@CR14],[@CR31],[@CR32]\], and an increase in one \[[@CR33]\] of the five eligible studies (see Table [2](#Tab2){ref-type="table"}).

Predictors of NSSI and DSH {#Sec5}
--------------------------

Analyzing the predictors of NSSI and DSH, only longitudinal predictors (existing at or before baseline) for NSSI during or at follow-up were included. A similar pattern could be found for NSSI and DSH. For NSSI, the predictor cited most often was previous NSSI, followed by depression, female gender, suicidality and psychological distress (see Table [3](#Tab3){ref-type="table"}).Table 3**Predictors and protective factors described in longitudinal studies using a NSSI definitionDomainPredictorNumber of studies**PersonalPredictor for NSSI during follow-up, existing before baselinePredictor for NSSI during follow-up, measured at baselineGenderFemale gender11NSSI(Previous) NSSI66Lifetime NSSI methods1NSSI thoughts1Low implicit and explicit aversion to NSSI stimuli1Forecasting future NSSI1SuicidalityHistory of suicide attempt3Suicidal ideation3Psychiatric symptomsDepressive symptoms7Conduct disorder/problems3Anxiety2BPD features (e.g. emotional reactivity, unstable relationship, unstable sense of self-image)2Drug and alcohol use impairment2Neurologic or psychiatric disease1Persistent psychotic experiences1Psychological impairmentPsychological distress5Hopelessness2Emotional problems1Problem behaviors1Lower self-esteem1Greater internalizing problems1Behavioral impulsivity1Negative emotions1Rumination1Attachment anxiety1Life eventsMore stressful or negative life events2Early sexual debut1Physical and sexual abuse1OtherNegative attributional style3Negative cognitive style1Excessive reassurance seeking1Being single (male)1Non-heterosexual sexual interest1Younger age1FamilyOnset of parental depression1Lower perceived family support1Problems with parents1SocialFriends' engagement in NSSI2Social adaption problems/1Problems with peers1Lack of social support1Relationship problems1Negative interactionsProtectiveHigher self esteem2Social support1Cognitive reappraisal1Parental care1Number of studies: Number of studies describing the specified predictor.Only predictors for NSSI at follow-up were included.

For DSH, higher scores of depression were described as predictor in the majority of studies, followed by female gender, lower self-esteem and alcohol/ drug use. Past behavior (previous DSH) as predictor of future DSH was described in two studies. Overall, numerous predictors overlapped in studies of NSSI and DSH.

Conclusion {#Sec6}
==========

Performing a systematic review of the literature, we were able to retrieve 32 studies, which assessed either NSSI or DSH longitudinally. Overall, both NSSI and DSH showed high volatility between assessment points with some studies reporting an increase, and some reporting a decrease of self-harming behaviors over time. Even within studies, there were high rates of discontinuation vs. new initiation of self-harming behaviors. A pattern emerged in studies of NSSI with studies being performed in young adolescents showing an upward trend in rates of NSSI, whereas studies in older adolescents or young adults showed a decrease in rates.

This could point to a natural course of NSSI with an increase in young adolescence and a decrease in late adolescence/young adulthood. The only study, which covered the whole time range from adolescence to adulthood, so far, is that of Moran et al. \[[@CR13]\]. Although the study focused on self-harm, thus also including suicidal behavior, the authors described a decrease in self cutting/burning behavior from adolescence to adulthood. Since this study is the most long-lasting and one of the largest studies in this field of research, it seems possible to suggest that both NSSI and DSH peak in adolescence at around 15 to 17 years and then remit in young to middle adulthood. Describing NSSI as a behavior that seems to change quickly, it makes sense to restrict possible diagnostic criteria of NSSI disorder to a short time span. As proposed in section three of the DSM 5 \[[@CR1]\], there should be repeated incidents of NSSI within a year to define the behavior. NSSI that has remitted for longer than a year or is not repetitive in its nature should not be classified as a disorder.

With regards to a developmental course, it would be interesting to follow up a broad range of risk behaviors over time. NSSI has been described as strong risk factor for later suicidality repeatedly (for review see \[[@CR34]\]), with suicide attempts also increasing in adolescence for the first time \[[@CR35]\]. Future studies therefore need to shed light on possible changes in behavior, i.e. NSSI possibly diminishing over time but being substituted by suicidal behavior or other risk seeking behavior such as illicit drug use.

Looking into predictors reported from longitudinal research, there seems to be an overlap between studies focusing on NSSI and those focusing on DSH. Namely, among the predictors found in several studies on DSH and NSSI, past self-harming behavior seems to be one of the strongest predictors for future behaviors. In addition, depressive symptomatology as well as female gender were reported in multiple studies. Knowledge about predictors could aid the development of preventive interventions, which could focus i.e. on the detection of depressive symptoms and need to be tailored for gender.

In addition to prevention programs, early interventions programs need to be established, focusing on those already injuring themselves and trying to stop the self-harming behavior which in itself is a predictor of future behavior. Several reviews have also identified social and family factors contributing to NSSI and DSH, suggesting preventive interventions should also address this topic (such as by integrating strategies against bullying).

However, due to the vast heterogeneity of the studies included in this review, general comments about the longitudinal course and predictors of NSSI/DSH are not easy to come up with. First, this is due to the different definitions of self-injurious behaviors used across studies. Further, assessment tools ranged from one question (i.e. "have you ever intentionally harmed yourself") to extensive interviews. Also, a number of studies did not assess self-injury homogeneously at all time-points (i.e. lifetime-NSSI at baseline and 3-months prevalence at follow-up), which made interpretation difficult at times. Moreover, follow-up periods were very heterogeneous, ranging from several months to 16 years. Therefore, a standardized definition of self-injurious behaviors and an establishment of evaluated tools for measuring NSSI seems to be well needed.

Limitations: This review presents a wide range of studies with different aims, therefore description of predictors and according to the numbers of studies in which the predictors were described is in no way meant as weighing predictors against each other. As some studies have looked at special aspects of NSSI or DSH, the range of predictors that were examined was restricted. Nevertheless, there seems to be a pattern of certain predictors that were described repeatedly and consistently throughout studies, which seems to be an interesting finding. Further, only studies in English or German language were included. This was due to language skills of the authors and limited resources, which did not allow for translation of articles in all relevant languages.
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